Korean Skincare Best Sellers — 16 August 2026 Baseline

The Olive Young skincare ranking on 16 August 2026 showed twelve positions we could read from the capture, and we wrote all twelve down. This is the first entry in a weekly series, so it has no previous week behind it. Nothing here is a rise, a fall or a new entry — those are things you can only calculate against something, and there is nothing yet to calculate against. This is a baseline: the first row of a table that starts paying for itself when the second row arrives.

A ranking is a poor thing to copy and a useful thing to read. Copied, it produces a product that reaches a shelf twelve to eighteen months after the shelf that justified it, because development, testing, registration and production all sit in between. Read, it gives something slower to go stale — which formats, which claim axes and which price band Korean buyers are standing in right now. That is the raw material a brief actually needs, and turning constraints into a development plan is easier when some of them come from outside your own assumptions.

Two notes on the material before the list. The format, claim and price labels used here are ours, applied to what the listing shows: the product name, the pack, the price on screen. They are not a reading of anyone's formula, and nothing below says that any product works. And the prices are what the shelf charged on the day of capture — not list prices. Several entries were sold as bundles, which changes what the number means; we come back to that.

What a Ranking Can and Cannot Be Read For

A retail ranking is one country, one retailer, one day, and it moves by the hour. Treated as evidence of what people want, it overstates itself badly. Treated as evidence of what is currently in front of Korean shoppers and clearing at that price, it is precise and cheap.

The difference matters because the two readings lead to different briefs. The first produces "make me the number one product." The second produces "the shelf I am entering is concentrated in these formats, sold on these axes, at this price — where do I want to sit relative to that?" Only the second question survives contact with a formulation lab.

There is a further limit worth stating plainly. Every product on this list was briefed a long time ago. What you are looking at is the output of decisions taken well before today, which makes a ranking a lagging indicator of briefs, not a leading one. It tells you what the current shelf looks like — a benchmark — and it does not tell you what the shelf will look like when your own product lands on it. For that, what brand owners are currently asking to have made is the better signal, and the two are worth reading together.

The Skincare Top Twelve, 16 August 2026

Product and brand names stay in Korean. Romanising them would create names that cannot be searched and cannot be checked, and the Korean name is the original. Names are reproduced as they appeared, including the promotional brackets, because those brackets carry the bundle information discussed below.

Two brands appear twice — 동아제약 at 9 and 11, 셀리맥스 at 5 and 12 — and in both cases the two entries sit on different claim axes rather than being variants of one product. That is worth noting as a fact about the list, and nothing more: we are not ranking, rating or recommending any of these products, and we did not make any of them.

Format: Seven Thin Liquids and Five Emulsions

Counted across the twelve, the split is five serums, five creams and two ampoules. Serum and ampoule together — the thin, leave-on liquids that ship in small bottles — hold seven of the twelve positions. Cream holds the other five. No toner, no essence, no cleanser, no mask appears at all in what the capture showed.

Every top-five position is a serum or an ampoule

The counts by themselves under-describe the pattern. Split the list at rank five and it separates cleanly: the top five are three serums and two ampoules, with no cream among them. Every cream on the list sits at rank six or below.

For a brief, that is a more actionable statement than the raw distribution. The formats currently occupying the head of this list are small-volume leave-on liquids, and the entry ticket to that part of the shelf is a thin liquid in a 15–100 ml pack. If your concept is a cream, this snapshot does not say the category is closed — five of twelve is not a small share — but it does say the cream positions on this particular list are the ones further down it.

The production consequences run the other way from the intuition. A thin aqueous serum is often the simpler bulk and the harder pack: the value, the cost and most of the lead time concentrate in the components — a dropper assembly, an airless pump, a fine-gauge applicator. Two of the top five ship in 15 ml, which is a small fill in a comparatively expensive piece of hardware. Anyone briefing into this part of the shelf should treat serum and ampoule formats and their filling requirements and the choice between an airless pump and a dropper as the same decision, taken early, rather than as packaging that gets picked after the formula is approved.

Cream sits below, and it is a different production job

The five creams are a different brief in every respect that matters to a factory. An emulsion has a minimum sensible batch behaviour that a thin liquid does not, and fills of 30–80 ml into jars and tubes carry their own component set. One of the five is described on the pack as a gel cream, which is the boundary case: sold as a cream, and closer to the thin-liquid group in how it is likely to be made and filled.

If the concept is an emulsion, cream and moisturiser development and the container decision should be settled together, because a jar, a tube and an airless bottle are three different products from a stability and a filling point of view even when the bulk is identical.

Claims: Where the Shelf Is Crowded

Applying our claim tags to what the packs say, twenty-eight tags fall across the twelve products. The axes that repeat:

• Hydration — 4. The single most common axis on the list.
• Blemish — 3 and soothing — 3. The two next largest, and frequently on the same packs.
• Cica — 2, firming — 2, hyaluronic — 2, pigmentation — 2, pore — 2.
• One each: barrier, brightening, cooling, eye, PDRN, retinol, sebum, tranexamic.

Hydration is the widest axis

Hydration appears on four packs, and on two of those the pack names hyaluronic acid on the front. That is the pattern worth taking into a brief: the crowded axis is not being sold as a benefit alone, it is being sold through a named ingredient. The consumer-facing claim and the ingredient story have collapsed into one another, and a brief that specifies a benefit without deciding what will be named on the front of the pack has left the most visible decision to someone else.

Soothing behaves the same way — both soothing-led packs name a centella-family ingredient, which is why a centella and cica soothing line reads as a format decision as much as an ingredient one. And the pigmentation pair splits: one names tranexamic acid, the other does not name anything. Both are legitimate routes. They are not the same brief.

We should be exact about what this is evidence of. It shows what is being said and what is selling at the same time. It is not evidence that any ingredient does anything, and this article does not make that claim on anyone's behalf.

The single-entry axes

Eight axes appear exactly once: barrier, brightening, cooling, eye, PDRN, retinol, sebum, tranexamic. A single appearance is not a trend and one week of data cannot tell you whether these are arriving, leaving or simply stable at one position. What they do mark is the part of the shelf that is not crowded — and thinness cuts both ways. There is less to compete with, and less evidence that the axis pulls volume.

Two of them are the sort of specific, named actives that a brief has to commit to early rather than late, because they change the packaging and stability conversation as much as the formulation one. PDRN in serum and ampoule formats is one; the entry on our retinol axis is the other, and that axis in particular tends to decide the container before anything else is settled.

Price: One Band Holds Three Quarters of the List

Nine of the twelve sold in the 20,000–30,000 KRW band on the day. Two sold in the 30,000–50,000 band, one below 20,000. Every price was legible on the capture, so there are no unknowns here — when a future week has an unreadable price we will leave it blank rather than guess at it.

Three quarters of a list inside a single 10,000-won band is a narrow shelf. The practical reading for a brief is a constraint, not a target: a concept that assumes a retail price far above or far below that band is not benchmarking against this list, and should say so explicitly rather than quietly. The two entries above the band are both creams with a specific, named claim. The one below it is the gel cream, at the largest fill on the list.

Note what the band is not. It is the price a shopper paid on 16 August 2026, in a week of heavy promotion — 올영픽, 단독기획, review events, 1+1. Retail price sets the ceiling that unit cost has to fit under, and the space between them is where formulation, components, decoration and volume all have to live. The mechanics of that arithmetic, and why one number cannot be quoted without knowing the packaging route, are set out in what actually sets the minimum on a production run.

Reading This Into a Brief

Benchmark the constraint set, not the winner

The useful output of a list like this is not a product to imitate. It is a set of four numbers that a brief can be written against: a format (thin leave-on liquid, or emulsion), a fill size (15–100 ml for the liquids, 30–80 ml for the creams), a claim axis (crowded or thin, and named or unnamed), and a price band. Those four decide most of what a factory needs to know before it can answer anything useful, and they are exactly what a brief to a formulation lab should carry.

Naming a benchmark product is legitimate and we ask for it — a link to a comparable product tells a development team more about texture and finish than a paragraph of adjectives can. What does not work is naming a benchmark and then contradicting it: a 15 ml dropper serum benchmark with a 100 ml jar brief describes two different products.

The bundle is part of the product

Seven of the twelve entries carry a bundle or promotion marker in the name: 1+1, 기획, 더블 기획, 리필, 대용량. The rank-one entry is 50+50 ml. That is not a footnote — it changes the physical product. A 1+1 is two primary containers and one secondary pack; a 기획 set is its own carton, artwork and packing operation; a refill is a different container altogether.

The consequence for a brief is that a bundle has to be decided before the components are, not after the product exists. Deciding it late means re-specifying secondary packaging, re-doing artwork, and re-planning the packing line for a format that was never quoted. Component and container selection is where that decision lands, and the cost of moving it late is the reason it belongs in the first conversation rather than the fourth.

If a benchmark on this list is the shape of the product you want, Korean skincare ODM development is the route where the base formula, the components and the bundle format get settled together rather than in sequence.

What This Baseline Does Not Show

Everything in this article is one capture of one category on one retailer on one day. From a single week, the following are simply not available, and we will not manufacture them:

• Movement. No rises, no falls, no entries, no exits. Those need a second week, and we calculate them rather than counting them by eye — reading two screenshots side by side and tallying differences by hand is reliably wrong past about ten rows.
• Durability. Whether the head of this list is stable or churns weekly. Four weeks will start to answer it; one cannot.
• Volume. A rank is an ordering, not a quantity. Nothing here says how much anything sold.
• Formulas. We know what the packs say. We do not know what is in them, at what level, and we do not write as though we do.

The point at which this series earns its keep is roughly a month in, when "in the top twelve every week for four weeks" and "gone after three" become statements we can make from calculation rather than impression. That is the version of this data that belongs in a brief.

Frequently Asked Questions

Why not just copy the number one product?

Because you would arrive late against a shelf that has moved, and because rank one on any given week is the least reproducible thing on the list — it reflects promotion, bundle economics and a review cycle you cannot see. The reproducible material is the constraint set: format, fill size, claim axis, price band. Those are stable enough over a month to brief against, and they are what a development team can actually act on.

The list mixes serums, ampoules and creams. Are those different projects?

Yes, and the difference is larger than the category label suggests. A thin leave-on liquid and an emulsion behave differently in the vessel, need different container decisions and carry different component costs. On this list the liquids also ship in much smaller fills than the creams, which changes the ratio of hardware cost to bulk cost substantially. Two products on the same list can be two entirely different production jobs.

Does a crowded claim axis mean I should avoid it?

Not necessarily, and the snapshot cannot answer it either way. A crowded axis has demonstrated pull and a lot of competitors; a thin one has less of both. What the snapshot does say is that on the crowded axes here, the packs are naming a specific ingredient on the front rather than claiming a benefit alone — so if you enter a crowded axis, the decision about what gets named belongs in the brief rather than in a later packaging review.

Why are there no minimum order quantities in this article?

Because there is no single number to quote. A minimum falls out of the binding constraint on a specific project — the bulk batch, the container, the components, the decoration setup — and it moves when the packaging route moves. A list of retail products cannot tell you which constraint would bind on your version of one, and quoting a figure without that would be guesswork presented as information.

This page is general information for manufacturing planning. It is not legal or regulatory advice, it has no legal effect, and no rights can be derived from it. Requirements change by market and over time — before acting on anything here, confirm the current position with the authority concerned or with qualified counsel.